Insider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) CEO Sells 92,001 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMTGet Free Report) CEO David Kirn sold 92,001 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $27.13, for a total value of $2,495,987.13. Following the completion of the transaction, the chief executive officer now directly owns 1,059,153 shares in the company, valued at approximately $28,734,820.89. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

David Kirn also recently made the following trade(s):

  • On Tuesday, January 23rd, David Kirn sold 5,696 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $18.41, for a total value of $104,863.36.
  • On Thursday, January 4th, David Kirn sold 40,732 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $20.31, for a total value of $827,266.92.

4D Molecular Therapeutics Stock Performance

Shares of 4D Molecular Therapeutics stock traded down $0.78 on Monday, hitting $27.85. The stock had a trading volume of 1,930,662 shares, compared to its average volume of 1,591,509. The firm has a market capitalization of $1.19 billion, a P/E ratio of -10.20 and a beta of 2.63. 4D Molecular Therapeutics, Inc. has a twelve month low of $9.44 and a twelve month high of $35.61. The stock has a 50 day moving average of $19.40 and a 200 day moving average of $15.74.

4D Molecular Therapeutics (NASDAQ:FDMTGet Free Report) last posted its earnings results on Thursday, November 9th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.43. The business had revenue of $20.20 million during the quarter, compared to analyst estimates of $6.41 million. 4D Molecular Therapeutics had a negative return on equity of 34.73% and a negative net margin of 436.30%. Equities analysts expect that 4D Molecular Therapeutics, Inc. will post -2.54 earnings per share for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently made changes to their positions in the business. Bfsg LLC bought a new stake in 4D Molecular Therapeutics in the 4th quarter worth about $30,000. International Assets Investment Management LLC bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $36,000. US Bancorp DE increased its stake in 4D Molecular Therapeutics by 580.7% in the fourth quarter. US Bancorp DE now owns 1,797 shares of the company’s stock worth $36,000 after purchasing an additional 1,533 shares during the period. Lazard Asset Management LLC lifted its holdings in 4D Molecular Therapeutics by 44.2% during the 2nd quarter. Lazard Asset Management LLC now owns 2,190 shares of the company’s stock valued at $38,000 after buying an additional 671 shares in the last quarter. Finally, Ensign Peak Advisors Inc increased its position in 4D Molecular Therapeutics by 167.9% during the 3rd quarter. Ensign Peak Advisors Inc now owns 7,180 shares of the company’s stock valued at $58,000 after purchasing an additional 4,500 shares during the period.

Analysts Set New Price Targets

Several research firms recently weighed in on FDMT. Leerink Partnrs raised 4D Molecular Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Wednesday, October 18th. BMO Capital Markets raised their price target on shares of 4D Molecular Therapeutics from $50.00 to $70.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. SVB Leerink upgraded shares of 4D Molecular Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 price target on the stock in a research note on Wednesday, October 18th. Cantor Fitzgerald initiated coverage on shares of 4D Molecular Therapeutics in a research note on Tuesday, October 24th. They set an “overweight” rating and a $32.00 target price for the company. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $81.00 price objective on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $39.44.

Get Our Latest Report on FDMT

4D Molecular Therapeutics Company Profile

(Get Free Report)

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy.

Read More

Insider Buying and Selling by Quarter for 4D Molecular Therapeutics (NASDAQ:FDMT)

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.